36,120 Shares in Guardant Health, Inc. (NASDAQ:GH) Acquired by Tema Etfs LLC

Tema Etfs LLC purchased a new position in Guardant Health, Inc. (NASDAQ:GH) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 36,120 shares of the company’s stock, valued at approximately $1,103,000.

A number of other institutional investors also recently added to or reduced their stakes in the company. NewEdge Advisors LLC lifted its stake in Guardant Health by 13.5% in the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock worth $59,000 after acquiring an additional 230 shares during the last quarter. Summit Investment Advisors Inc. lifted its position in shares of Guardant Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company’s stock worth $377,000 after buying an additional 391 shares during the last quarter. Arizona State Retirement System lifted its position in shares of Guardant Health by 1.1% during the 4th quarter. Arizona State Retirement System now owns 35,639 shares of the company’s stock worth $1,089,000 after buying an additional 403 shares during the last quarter. Jones Financial Companies Lllp lifted its position in shares of Guardant Health by 43.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock worth $82,000 after buying an additional 817 shares during the last quarter. Finally, R Squared Ltd purchased a new stake in shares of Guardant Health during the 4th quarter worth approximately $26,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Performance

Shares of GH opened at $40.67 on Friday. The stock has a market capitalization of $5.04 billion, a P/E ratio of -11.42 and a beta of 1.49. The company’s fifty day moving average is $43.81 and its two-hundred day moving average is $39.64. Guardant Health, Inc. has a 1 year low of $20.14 and a 1 year high of $52.92.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $203.47 million for the quarter, compared to analysts’ expectations of $189.91 million. During the same period in the previous year, the company posted ($0.46) EPS. Guardant Health’s revenue was up 20.8% compared to the same quarter last year. Sell-side analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current year.

Insider Transactions at Guardant Health

In other news, CEO Amirali Talasaz sold 106,784 shares of the company’s stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the transaction, the chief executive officer now directly owns 2,202,672 shares of the company’s stock, valued at $107,952,954.72. This represents a 4.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 107,132 shares of company stock valued at $5,249,355 in the last ninety days. 6.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

GH has been the subject of several recent analyst reports. Stifel Nicolaus boosted their price objective on shares of Guardant Health from $53.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, May 1st. Guggenheim restated a “buy” rating and set a $56.00 price objective on shares of Guardant Health in a research report on Monday, February 24th. Morgan Stanley boosted their price objective on shares of Guardant Health from $42.00 to $52.00 and gave the stock an “overweight” rating in a research report on Thursday, March 6th. Piper Sandler reaffirmed an “overweight” rating and issued a $60.00 target price (up from $50.00) on shares of Guardant Health in a report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Twenty-one analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $52.32.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.